Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK's status as a global life science hub, the long-term government actions that continue to render the life-sciences sector attractive, and how the NHS is well-suited to the advent of big data and personalized medicine.
Can you introduce the BIA to our international readers?
"We have a place on the global [biotech] podium and would like to go further"
Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the International Society of Paediatric Oncology (SIOP) discusses the latest advancements in childhood cancer treatment, the…
Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient and patient organizations’ involvement in the decision-making process for therapy appraisals, the use of HTA,…
A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO,…
After a tumultuous year, AstraZeneca is creating a standalone vaccine unit and will begin to charge for its COVID-19 vaccine shot, having previously provided it at cost. PharmaBoardroom looks back…
In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global…
The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over…
See our Cookie Privacy Policy Here